- Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment
- Investors have been unimpressed by the 20% weight loss for patients, compared to market leader Eli Lilly's (LLY) Zepbound at up to 24%.
- In addition, some analysts worried about the safety profile when Amgen first released data, in November 2024, sending the stock down more than 30% that day.
Amgen's (AMGN) late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls patients in its phase 3 trial.
The company announced Monday that it has resolved some investors' safety and tolerability concerns about the drug. Rather than jumping from a low to high dose, Amgen will now get patients to the highest dose through a three-step dose escalation, starting at 21 mg and ending at 350 mg doses.
Amgen is one of several companies discussing GLP-1s at this week's American Diabetes Conference in Chicago. The company revealed the full data of its phase 2 data, showing 20% weight loss in obese individuals and 17% in those who also have Type 2 diabetes.
No comments:
Post a Comment